- Home
- ADVM vs ADAG Comparison
ADVM vs ADAG Comparison
Compare ADVM & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- ADAG
- Stock Information
- Founded
- ADVM 2006
- ADAG 2011
- Country
- ADVM United States
- ADAG China
- Employees
- ADVM N/A
- ADAG N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- ADAG Health Care
- Exchange
- ADVM Nasdaq
- ADAG Nasdaq
- Market Cap
- ADVM 140.6M
- ADAG 113.9M
- IPO Year
- ADVM 2014
- ADAG 2021
- Fundamental
- Price
- ADVM $7.21
- ADAG $3.17
- Analyst Decision
- ADVM Strong Buy
- ADAG Strong Buy
- Analyst Count
- ADVM 6
- ADAG 1
- Target Price
- ADVM $28.17
- ADAG $5.00
- AVG Volume (30 Days)
- ADVM 155.6K
- ADAG 142.8K
- Earning Date
- ADVM 11-07-2024
- ADAG 07-25-2024
- Dividend Yield
- ADVM N/A
- ADAG N/A
- EPS Growth
- ADVM N/A
- ADAG N/A
- EPS
- ADVM N/A
- ADAG N/A
- Revenue
- ADVM N/A
- ADAG $815,746.00
- Revenue This Year
- ADVM N/A
- ADAG N/A
- Revenue Next Year
- ADVM $5,848.83
- ADAG $2.70
- P/E Ratio
- ADVM N/A
- ADAG N/A
- Revenue Growth
- ADVM N/A
- ADAG N/A
- 52 Week Low
- ADVM $6.38
- ADAG $1.21
- 52 Week High
- ADVM $29.70
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- ADVM 53.08
- ADAG 60.13
- Support Level
- ADVM $6.54
- ADAG $2.60
- Resistance Level
- ADVM $7.22
- ADAG $3.10
- Average True Range (ATR)
- ADVM 0.34
- ADAG 0.22
- MACD
- ADVM 0.05
- ADAG 0.03
- Stochastic Oscillator
- ADVM 63.46
- ADAG 96.61
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.